Esophageal cancer, Gynecological cancer, Lung cancer
Conditions
Interventions
None listed
Sponsors
Hoshigaoka Medical Cennter
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) 18 years of age or older 2) PS0-2: Patients must be at a pathological level that allows them to receive various treatments for cancer and anticoagulation therapy. 3) Histologically or cytologically diagnosed cancer or expected to be diagnosed within the next 3 months. 4) Cases of VTE that occurred before, during, or after cancer treatment and cases scheduled for various cancer-related treatments (as normal controls) 5) Cases with the following cancers for which written consent for this study has been obtained Lung cancer, stomach cancer, liver cancer, bile duct cancer, gall bladder cancer, pancreatic cancer, colorectal cancer, gynecological cancer, urological cancer, sarcoma, breast cancer, lymphoma 6) To capture the characteristics of cancer-related VTE, it is preferable before anticoagulation is administered. However, in some cases, early initiation of treatment with anticoagulation may be desirable depending on the VTE diagnosis, so approval should be granted after specifying the medication status.
Exclusion criteria
Exclusion criteria: Cases with a prognosis of less than 3 months Cases of pregnancy Cases judged inappropriate to investigate by attending physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Elucidation of detail coagulation-fibrinolysis state before initial treatment for cancers in patients. Clarifying of existence of thrombosis in pre-treatment cancer patients. Revealing rate of thrombotic and bleeding events after starting of thrombolysis therapies. | — |
Countries
Japan
Contacts
Public ContactCHIKAO YASUDA
Hoshigaoka Medical Center Department of Vascular Surgery
Outcome results
None listed